Cited by 494Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

The DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index.

Cytology versus HPV testing for cervical cancer screening in the general population

Open access

Koliopoulos, George, Nyaga, Victoria N, Santesso, Nancy, Bryant, Andrew, Martin-Hirsch, Pierre PL, Mustafa, Reem A, Schünemann, Holger, Paraskevaidis, Evangelos, Arbyn, Marc·2017·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd008587.pub2PMC PMC6483676

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Cervical cancer screening has traditionally been based on cervical cytology. Given the aetiological relationship between human papillomavirus (HPV) infection and cervical carcinogenesis, HPV testing has been proposed as an alternative screening test. OBJECTIVES: To determine the diagnostic accuracy of HPV testing for detecting histologically confirmed cervical intraepithelial neoplasias (CIN) of grade 2 or worse (CIN 2+), including adenocarcinoma in situ, in women participating in primary cervical cancer screening; and how it compares to the accuracy of cytological testing (liquid-based and conventional) at various thresholds. SEARCH METHODS: We performed a systematic literature search of articles in MEDLINE and Embase (1992 to November 2015) containing quantitative data and handsearched the reference lists of retrieved articles. SELECTION CRITERIA: We included comparative test accuracy studies if all women received both HPV testing and cervical cytology followed by verification of the disease status with the reference standard, if positive for at least one screening test. The studies had to include women participating in a cervical cancer screening programme who were not being followed up for previous cytological abnormalities. DATA COLLECTION AND ANALYSIS: We completed a 2 x 2 table with the number of true positives (TP), false positives (FP), true negatives (TN), and false negatives for each screening test (HPV test and cytology) used in each study. We calculated the absolute and relative sensitivities and the specificities of the tests for the detection of CIN 2+ and CIN 3+ at various thresholds and computed sensitivity (TP/(TP + TN) and specificity (TN/ (TN + FP) for each test separately. Relative sensitivity and specificity of one test compared to another test were defined as sensitivity of test-1 over sensitivity of test-2 and specificity of test-1 over specificity of test-2, respectively. To assess bias in the studies, we used the Quality Assessment of Diagnostic test Accuracy Studies (QUADAS) tool. We used a bivariate random-effects model for computing pooled accuracy estimates. This model takes into account the within- and between-study variability and the intrinsic correlation between sensitivity and specificity. MAIN RESULTS: We included a total of 40 studies in the review, with more than 140,000 women aged between 20 and 70 years old. Many studies were at low risk of bias. There were a sufficient number of included studies with adequate methodology to perform the following test comparisons: hybrid capture 2 (HC2) (1 pg/mL threshold) versus conventional cytology (CC) (atypical squamous cells of undetermined significance (ASCUS)+ and low-grade squamous intraepithelial lesions (LSIL)+ thresholds) or liquid-based cytology (LBC) (ASCUS+ and LSIL+ thresholds), other high-risk HPV tests versus conventional cytology (ASCUS+ and LSIL+ thresholds) or LBC (ASCUS+ and LSIL+ thresholds). For CIN 2+, pooled sensitivity estimates for HC2, CC and LBC (ASCUS+) were 89.9%, 62.5% and 72.9%, respectively, and pooled specificity estimates were 89.9%, 96.6%, and 90.3%, respectively. The results did not differ by age of women (less than or greater than 30 years old), or in studies with verification bias. Accuracy of HC2 was, however, greater in European countries compared to other countries. The results for the sensitivity of the tests were heterogeneous ranging from 52% to 94% for LBC, and 61% to 100% for HC2. Overall, the quality of the evidence for the sensitivity of the tests was moderate, and high for the specificity.The relative sensitivity of HC2 versus CC for CIN 2+ was 1.52 (95% CI: 1.24 to 1.86) and the relative specificity 0.94 (95% CI: 0.92 to 0.96), and versus LBC for CIN 2+ was 1.18 (95% CI: 1.10 to 1.26) and the relative specificity 0.96 (95% CI: 0.95 to 0.97). The relative sensitivity of HC2 versus CC for CIN 3+ was 1.46 (95% CI: 1.12 to 1.91) and the relative specificity 0.95 (95% CI: 0.93 to 0.97). The relative sensitivity of HC2 versus LBC for CIN 3+ was 1.17 (95% CI: 1.07 to 1.28) and the relative specificity 0.96 (95% CI: 0.95 to 0.97). AUTHORS' CONCLUSIONS: Whilst HPV tests are less likely to miss cases of CIN 2+ and CIN 3+, these tests do lead to more unnecessary referrals. However, a negative HPV test is more reassuring than a negative cytological test, as the cytological test has a greater chance of being falsely negative, which could lead to delays in receiving the appropriate treatment. Evidence from prospective longitudinal studies is needed to establish the relative clinical implications of these tests.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008587.pub2

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Effect of Riding as an Alternative Treatment for Children with Cerebral Palsy: A Systematic Review and Meta-Analysis
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A. T., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,587
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
Principles and Practice of Screening for Disease.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-5-1085_2 · Cited by 3,251
Human papillomavirus and cervical cancer
SCHIFFMAN, M. H., Castle, P. E., Jerónimo, J., Rodríguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 3,135
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910

Flagged first, then by citations

Show all 145 references

3 of the 145 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

McAdam, 2010, Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting, PLoS ONE, 5, e13266, 10.1371/journal.pone.0013266 · DOI
Castle, 2011, Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study, Lancet Oncology, 12, 880, 10.1016/S1470-2045(11)70188-7 · DOI
Chan, 1999, NASBA and other transcription-based amplification methods for research and diagnostic microbiology, Review Medical Microbiology, 10, 184
International Agency for research on Cancer, 2005, Cervix Cancer Screening: IARC Handbooks of Cancer Prevention, 10
IARC working group on the evaluation of carcinogenic risks to humans, 2007, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90: Human Papilloma viruses
Kjaer S Long term predictive value of HPV testing (the Danish prospective cohort study) 21st International Human Papillomavirus Conference Mexico City Abstract 339
Luesley, 2004, NHSCSP Publication No. 20. Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme
Reitsma JB Rutjes AWS Whiting P Vlassov VV Leeflang MMG Deeks JJ Chapter 9: Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2009 Available from: srdta.cochrane.org/
Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014

Sorted by citations

Items 101–200 of 493

A direct comparison of four high‐risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low‐resource settings
Xue, P., Gao, L., Yin, J., Han, L., Zhao, J., Li, L., Seery, S., Han, X.-Y., Li, T., Jiang, Y., et al. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25451 · Cited by 21
Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia
Hu, L., Mwanahamuntu, M., Sahasrabuddhe, V. V., Barrett, C., Horning, M. P., Shah, I., Laverriere, Z., Banik, D., Ji, Y., Shibemba, A. L., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7355 · Cited by 20
MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer
Pisarska, J., & Baldy-Chudzik, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113668 · Cited by 20
Acceptability of extending HPV-based cervical screening intervals from 3 to 5 years: an interview study with women in England
Nemec, M., Waller, J., Barnes, J., & Marlow, L. A. V. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058635 · Cited by 19
Evaluation of p16/Ki‐67 dual‐stain as triage test for high‐risk HPV ‐positive women: A hospital‐based cross‐sectional study
Chen, X., Chen, C., Liu, L., Dai, W., Zhang, J., Han, C., & Zhou, S. (2022) · Cancer Cytopathology · doi:10.1002/cncy.22628 · Cited by 19
Quantitative analysis of abnormalities in gynecologic cytopathology with deep learning
Ke, J., Shen, Y., Lu, Y., Deng, J., Wright, J. D., Zhang, Y., Huang, Q., Wang, D., Jing, N., Liang, X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00537-1 · Cited by 19
Performance of screening tools for cervical neoplasia among women in low- and middle-income countries: A systematic review and meta-analysis
Smith, S. K., Nwosu, O., Edwards, A., Zerihun, M., Chung, M. H., Suvada, K., & Ali, M. K. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001598 · Cited by 25
Advances in Etiopathological Role and Control of HPV in Cervical Cancer Oncogenesis
Kombe, A. J. K., Zoa‐Assoumou, S., Bounda, G., Biteghe, F. A. N., Jin, T., & Zouré, A. A. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810245 · Cited by 18
From Diagnosis to Treatment: Exploring the Latest Management Trends in Cervical Intraepithelial Neoplasia
Gupta, S., Nagtode, N., Chandra, V., & Gomase, K. (2023) · Cureus · doi:10.7759/cureus.50291 · Cited by 18
Transition from opportunistic cytological to organized screening program with DNA-HPV testing detected prevalent cervical cancers 10 years in advance
Teixeira, J. C., Vale, D. B., Campos, C. S., Polegatto, I., Bragança, J. F., Discacciati, M. G., & Zeferino, L. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-71735-2 · Cited by 21
Targeting HPV for the prevention, diagnosis, and treatment of cervical cancer
Ni, H., Huang, C., Ran, Z., Li, S., Kuang, C., Zhang, Y., & Yuan, K. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae046 · Cited by 27
“They Should Be Asking Us”: A Qualitative Decisional Needs Assessment for Women Considering Cervical Cancer Screening
Wood, B., Russell, V. L., El‐Khatib, Z., McFaul, S. M., Taljaard, M., Little, J., & Graham, I. D. (2018) · Global Qualitative Nursing Research · doi:10.1177/2333393618783632 · Cited by 20
A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention
Nowakowski, A. M., Arbyn, M., Turkot, M. H., Wieszczy, P., Miłosz, K., Kaminski, M. F., Didkowska, J. A., Bidziński, M., Olszewski, W. T., Wielgoś, M., et al. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000528 · Cited by 18
Self-citation
Comprehensive Cervical Cancer Prevention in Tanzania (CONCEPT) study: Cohort profile
Mchome, B. L., Swai, P., Wu, C. S., Katanga, J., Kahesa, C., Manongi, R. N., Mwaiselage, J. D., Kjær, S. K., Rasch, V., & Linde, D. S. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038531 · Cited by 18
Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study
Devine, A., Vahanian, A., Sawadogo, B., Zan, S., Bocoum, F. Y., Kelly, H. A., Gilham, C., Nagot, N., Ong, J. J., Legood, R., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248832 · Cited by 20
Raman Spectroscopy of Liquid-Based Cervical Smear Samples as a Triage to Stratify Women Who Are HPV-Positive on Screening
Traynor, D., Martin, C. M., White, C. M., Reynolds, S., D’Arcy, T., O’Leary, J. J., & Lyng, F. M. (2021) · Cancers · doi:10.3390/cancers13092008 · Cited by 18
Clinical evaluation of a real-time optoelectronic device in cervical cancer screening
Wei, Y., Wang, W., Cheng, M., Hong, Z., Gu, L., Niu, J., Di, W. J., & Qiu, L. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.09.027 · Cited by 17
Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy
Traboulsi-Garet, B., Jorba‐García, A., Camps‐Font, O., Alves, F. A., Figueiredo, R., & Valmaseda‐Castellón, E. (2022) · Clinical Oral Investigations · doi:10.1007/s00784-022-04383-3 · Cited by 19
Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention
Surriabre, P., Torrico, A., Vargas, T., Ugarte, F., Rodríguez, P., & Fontaine, V. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4527-9 · Cited by 18
Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy
Gupta, A., Dagar, G., Das, S. K., Chauhan, R., Shankar, A., Sharma, D. N., Suri, V. S., Khan, M. A., Macha, M. A., Ahmed, I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-93152-9 · Cited by 16
Natural and synthetic drugs and formulations for intravaginal HPV clearance
Khamjan, N. A., Beigh, S., Algaissi, A. A., Megha, K., Lohani, M., Darraj, M. A., Kameli, N., Madkhali, F., & Dar, S. A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.016 · Cited by 16
Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing–Based Cervical Screen-and-Treat Program in El Salvador
Alfaro, K. M., Maza, M., Felix, J. C., Gage, J. C., Castle, P. E., Alonzo, T. A., Chacón, A., González, E., Soler, M., Rodriguez, G. C., et al. (2020) · JCO Global Oncology · doi:10.1200/go.20.00206 · Cited by 20
Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women
Huang, M., Wang, T., Li, M., Qin, M., Deng, S., & Chen, D. (2024) · BMC Cancer · doi:10.1186/s12885-024-12696-7 · Cited by 15
Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination
Henschke, N., Bergman, H., Buckley, B. S., Crosbie, E. J., Dwan, K. M., Golder, S., Kyrgiou, M., Loke, Y. K., McIntosh, H. M., Probyn, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015363.pub2 · Cited by 17
Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme
Bokan, T., Ivanuš, U., Jerman, T., Takač, I., & Arko, D. (2021) · Radiology and Oncology · doi:10.2478/raon-2021-0001 · Cited by 15
Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city—Lessons learned from the Amazon city of Manaus, Brazil
Torres, K. L., Rondon, H. H. D. M. F., Martins, T. R., Martins, S. J., Ribeiro, A. K. D. C., Raiol, T., Marques, C. P., Corrêa, F. D. M., Migowski, A., Minuzzi-Souza, T. T. C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258539 · Cited by 15
Healthcare providers’ knowledge, attitude, and practice towards cervical cancer screening in Sub-Saharan Africa: systematic review and meta-analysis
Delie, A. M., Bogale, E. K., Anagaw, T. F., Tiruneh, M. G., Fenta, E. T., Endeshaw, D., Eshetu, H. B., Adal, O. T., Tareke, A. A., & Kebede, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1436095 · Cited by 15
Patterns of anxiety and distress over 12 months following participation in HPV primary screening
Marlow, L. A. V., McBride, E., Ridout, D. A., Forster, A. S., Kitchener, H. C., & Waller, J. (2021) · Sexually Transmitted Infections · doi:10.1136/sextrans-2020-054780 · Cited by 15
Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China
Wu, Z., Li, T., Han, Y., Jiang, M., Yu, Y., Xu, H., Yu, L., Cui, J., Liu, B., Chen, F., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02078-2 · Cited by 14
Mise en place du programme national de dépistage organisé du cancer du col de l’utérus en France
Woronoff, A., Molinié, F., & Trétarre, B. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.11.013 · Cited by 15
Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high‐resolution microendoscopy to detect cervical precancer
Parra, S. G., López, L., Duque, A. R. M., Carns, J., Schwarz, R. A., Smith, C. A., Silvestre, M. O., Bazan, S. D., Escobar, P., Felix, J. C., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33454 · Cited by 15
Diagnostic accuracy of menstrual blood for human papillomavirus detection in cervical cancer screening: a systematic review
Chakravarti, P., Maheshwari, A., Tahlan, S., Kadam, P. R., Bagal, S. S., Gore, S., Panse, N. S., Deodhar, K., Chaturvedi, P., Dikshit, R. P., et al. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1427 · Cited by 15
Cervical Cancer Screening in the HPV-Vaccinated and Digital Era: Reassessing Strategies in Light of Artificial Intelligence and Evolving Risk
Galani, A., Zikopoulos, A., Moustakli, E., Potiris, A., Paraskevaidi, M., Arkoulis, I., Machairoudias, P., Stavrakaki, S. M., Kyrgiou, M., & Stavros, S. (2025) · Cancers · doi:10.3390/cancers17193179 · Cited by 17
Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis
Bergman, H., Henschke, N., Arévalo-Rodríguez, I., Buckley, B. S., Crosbie, E. J., Davies, J. C., Dwan, K. M., Golder, S., Loke, Y. K., Probyn, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015364.pub2 · Cited by 19
Advances in HPV Screening Tests for Cervical Cancer—A Review
Lucksom, P. G., Sherpa, M. L., Pradhan, A., Lal, S., & Gupta, C. (2021) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-021-01569-9 · Cited by 15
Characteristics of the vaginal microbiota and vaginal metabolites in women with cervical dysplasia
Yu, T., Gao, S., Jin, F., Yan, B., Wang, W., & Wang, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1457216 · Cited by 13
Cervical Cancer Screening in HIV-Positive Women in India: Why, When and How?
Boddu, A., Bhatla, N., Vashist, S., Mathur, S., Mahey, R., Natarajan, J., Malik, R., Vanamail, P., Rai, S., Kumari, A., et al. (2021) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-020-01419-0 · Cited by 13
In vitro and in vivo evaluation of a standardized Curcuma longa Linn formulation in cervical cancer
Paradkar, P. H., Juvekar, A. S., Barkume, M. S., Amonkar, A. J., Joshi, J. V., Soman, G., & Vaidya, A. (2021) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2021.06.002 · Cited by 13
Role of Self-Sampling for Cervical Cancer Screening: Diagnostic Test Properties of Three Tests for the Diagnosis of HPV in Rural Communities of Cuenca, Ecuador
Vega, B., Neira, V. A., Ortíz, J., Maldonado-Rengel, R., López, D., Paz, O. M., Gómez, A., Vicuña, M. J., Chicaiza, J. V. M., Benoy, I. H., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084619 · Cited by 13
Performance of a 7-Type HPV mRNA Test in Triage of HPV DNA Primary Screen Positive Women Compared to Liquid-Based Cytology
Sørbye, S. W., Falang, B. M., & Antonsen, M. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4020008 · Cited by 13
Cervical screening in Western Kazakhstan: Liquid-based cytology ‘Cell Scan’ versus azur-eosin staining
Balmagambetova, S. K., Gabutti, G., Koyshybaev, A. K., Martellucci, C. A., Urazayev, O., Kanshaiym, S., & Bekova, K. (2019) · Journal of Medical Screening · doi:10.1177/0969141319885409 · Cited by 13
T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates
Christley, S., Ostmeyer, J., Quirk, L., Zhang, W., Sirak, B. A., Giuliano, A. R., Zhang, S., Monson, N. L., Tiro, J. A., Lucas, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624230 · Cited by 12
The Impact of COVID-19 Pandemic on Screening Programs for Cervical Cancer Prevention Across Europe
Carcopino, X., Cruickshank, M. E., Leeson, S. C., Redman, C. W. E., & Nieminen, P. (2022) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000677 · Cited by 12
Grupos de Expertos de Cáncer del PAPPS. Recomendaciones de Prevención del Cáncer. Actualización PAPPS 2020
Marzo‐Castillejo, M., Vallespín, C. V., Bellas-Beceiro, B., Bartolomé-Moreno, C., Ginés-Díaz, Y., & Melús-Palazón, E. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.09.003 · Cited by 12
Cervical screening in high-income countries: the need for quality assurance, adjunct biomarkers and rational adaptation to HPV vaccination
Sundström, K., Herweijer, E., & Wang, J. (2020) · Preventive Medicine · doi:10.1016/j.ypmed.2020.106382 · Cited by 12
Study to determine efficacy of urinary HPV 16 & HPV 18 detection in predicting premalignant and malignant lesions of uterine cervix
John, J. H., Halder, A., Purwar, S., Pushpalatha, K., Gupta, P., & Dubey, P. (2022) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14486 · Cited by 13
A systematic review and meta‐analysis of diagnostic accuracy of HPV tests for the screening of cervical cancer in low‐resource settings
Magdi, R., Elshafeey, F., Elshebiny, M., Kamel, M., Abuelnaga, Y. G., Ghonim, M., Nabhan, A. F., & ECEBM Working Group (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13455 · Cited by 13
Incorporation of human papillomavirus self-sampling into the revised National Cervical Screening Program: a qualitative study of GP experiences and attitudes in rural New South Wales
Foo, Y. M., Goswami, P., Grogin, J., Hargan, E., Thangarajah, M., Dutton, T., Mendel, S., & Bailey, J. (2021) · Australian Journal of Primary Health · doi:10.1071/py20209 · Cited by 12
Diagnostic value of colposcopy in patients with cytology-negative and HR-HPV-positive cervical lesions
Liu, Y., Liao, J., Yi, X., Pan, Z., Pan, J., Sun, C., Zhou, H., & Meng, Y. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06415-5 · Cited by 12
Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model
Kayyal, M., Bolhassani, A., Noormohammadi, Z., & Sadeghizadeh, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119945 · Cited by 12
Cervical cancer prevention: Human papillomavirus testing as primary screening
Desai, S., Zhu, M. J., & Lapidos‐Salaiz, I. (2021) · Cancer · doi:10.1002/cncr.34006 · Cited by 11
Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management
Bowden, S. J., Ellis, L. B., Kalliala, I. E. J., Paraskevaidi, M., Tighe, J., Kechagias, K. S., Doulgeraki, T., Paraskevaidis, E. A., Arbyn, M., Flanagan, J. M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071534 · Cited by 11
Self-citation
HPV Testing and its Role in Cervical Cancer Screening
Clarke, M. A. (2023) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000793 · Cited by 11
Screening and prevention of HPV ‐related anogenital cancers in women living with HIV in Europe : Results from a systematic review
Krankowska, D. C., Mazzitelli, M., Uçak, H. A., Orviz, E., Karakoç, H. N., Mortimer, H., Aebi‐Popp, K., & Gilleece, Y. C. (2024) · HIV Medicine · doi:10.1111/hiv.13602 · Cited by 14
Human papillomavirus self-sampling versus provider-sampling in low- and middle-income countries: a scoping review of accuracy, acceptability, cost, uptake, and equity
Otieno, J. A., Were, L. M., Nyanchoka, M., Olwanda, E. E., Mulaku, M., Sem, X., Kohli, M., Markby, J. L., Muriuki, A., & Ochodo, E. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1439164 · Cited by 15
Cervical cancer prediction using machine learning models based on routine blood analysis
Su, J., Lu, H., Zhang, R., Cui, N., Chen, C., Si, Q., & Song, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-08166-0 · Cited by 11
Nouvelles recommandations pour le dépistage du cancer du col de l’utérus en France
Baraquin, A., Pépin‐Puget, L., Floerchinger, P., Lepiller, Q., & Prétet, J. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.006 · Cited by 11
Functions of Traditional Chinese Medicine Combined with Recombinant Human Interferon α2b in Cervical Intraepithelial Neoplasias Patients
Ding, W., Xiaoyan, L., Baojun, J., & Wang, Z. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6881720 · Cited by 11
Analysis of the role of the human papillomavirus 16/18 E7 protein assay in screening for cervical intraepithelial neoplasia: a case control study
Kong, L., Xiao, X., Lou, H., Liu, P., Song, S., Liu, M., Xu, T., Zhang, Y., Li, C., Guan, R., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07483-z · Cited by 11
Replacing the Pap Test With Screening Based on Human Papillomavirus Assays
Massad, L. S. (2018) · JAMA · doi:10.1001/jama.2018.7911 · Cited by 11
Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?
Godoy, L. R., Resende, J. C. P., Guimarães, Y. M., Pedrão, P. G., dos Reis, R., & Longatto‐Filho, A. (2022) · Cancers · doi:10.3390/cancers14112612 · Cited by 14
Turning the tide—Recommendations to increase cervical cancer screening among women who are underscreened
Descamps, P., Dixon, S., Jose, F. X. B., Kyrgiou, M., Monsonégo, J., Neisingh, O., Nguyen, L., O’Connor, M., & Smith, J. S. (2024) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15600 · Cited by 12
Cervical cytology screening using the fused deep learning architecture with attention mechanisms
Jin, Y., Ma, J., Lian, Y., Wang, F., Wu, T., Hu, H., & Feng, Z. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.112202 · Cited by 10
Does use of anal cytology as a triage test improve the performance of high‐risk human papillomavirus screening in gay and bisexual men for anal cancer prevention?
Jin, F., Poynten, I. M., Hillman, R. J., Law, C., Molano, M., Fairley, C. K., Garland, S. M., Templeton, D. J., Grulich, A. E., Roberts, J. M., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35185 · Cited by 10
The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection
Su, H., Jin, X., Kong, L., You, Y., Wu, H., Liou, Y., & Li, L. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03005-5 · Cited by 10
Comparison of nylon‐flocked swab and Dacron swab cytology for anal HSIL detection in transgender women and gay, bisexual, and other men who have sex with men
Wiley, D. J., Hsu, H., Ganser, M. A., Brook, J. K., Elashoff, D. A., Moran, M., Young, S. A., Joste, N. E., Mitsuyasu, R. T., Darragh, T. M., et al. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22114 · Cited by 10
miRNAs signature as potential biomarkers for cervical precancerous lesions in human papillomavirus positive women
González-Ramírez, M. I., Cardona, Y. T., Agudelo, M. C., López, C., Florez-Acosta, J. J., Agudelo, S., Garai, J., Li, L., Orozco, C. A., Zabaleta, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36421-9 · Cited by 10
Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing
Cuschieri, K. S., Schuurman, R., & Coughlan, S. (2019) · Cytopathology · doi:10.1111/cyt.12679 · Cited by 10
Сontroversial issues in cytological screening for cervical cancer (literature review)
Новик, В. И. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-2-63-71 · Cited by 10
Maximising the acceptability of extended time intervals between screens in the NHS Cervical Screening Programme: An online experimental study
Hill, E., Němec, M., Marlow, L. A. V., Sherman, S. M., & Waller, J. (2020) · Journal of Medical Screening · doi:10.1177/0969141320970591 · Cited by 10
Detection of Cervical Lesions and Cancer in Air-Dried Cytologic Smears by Combined Analysis of mRNA and miRNA Expression Levels
Ivanov, M., Titov, S. E., Dzyubenko, V. V., Glushkov, S. A., Krasilnikov, S. E., Mansurova, A. S., Malek, A. V., Берлев, И. В., Prisyazhnaya, T., Kuleshova, S. V., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.01.016 · Cited by 10
Challenges in Comparative Meta-Analysis of the Accuracy of Multiple Diagnostic Tests
Veroniki, A. A., Tsokani, S., Rücker, G., Mavridis, D., & Takwoingi, Y. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1566-9_18 · Cited by 10
Clinical Characteristics and Detection Sensitivity of Cervical Cancer Screening in Vaginal Intraepithelial Neoplasia
Chen, Y., Chen, Q., Xue, H., Zheng, J., Chen, J., & Zheng, X. (2023) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000793 · Cited by 9
Cervical cancer prevention in Southern Africa: A review of national cervical cancer screening guidelines in the Southern African development community
Adams, R., & Botha, M. H. (2024) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2024.100477 · Cited by 9
Self-Screening for Cervical Cancer Offered through a Digital Platform in a Region of British Columbia with Lower Screening Rates
Smith, L., Booth, A., Racey, C. S., Smith, B., Prabhakaran, A., Dabee, S., Hong, Q., Niazi, N., & Ogilvie, G. S. (2024) · Current Oncology · doi:10.3390/curroncol31090399 · Cited by 10
Population-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30 years and above in Germany
Liang, L. A., Tanaka, L. F., Radde, K., Bussas, U., Ikenberg, H., Heideman, D. A. M., Meijer, C. J. L. M., Blettner, M., & Klug, S. J. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09827-7 · Cited by 9
Confronting the human papillomavirus–HIV intersection: Cervical cytology implications for Kenyan women living with HIV
Kangethe, J. M., Gichuhi, S., Odari, E. O., Pintye, J. C., Mutai, K. K., Abdullahi, L. H., Maiyo, A. K., & Mureithi, M. (2023) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v24i1.1508 · Cited by 9
HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial
Glińska, P., Komerska, K., Janik, B., Olkowicz, J., Jędrzejewska, I., Macios, A., Wieszczy, P., Kaminski, M. F., Arbyn, M., & Nowakowski, A. M. (2023) · BMC Cancer · doi:10.1186/s12885-023-11597-5 · Cited by 9
Self-citation
Utilization of cervical cancer screening service among female health workforces in public health institutions in south east Ethiopia, a cross-sectional study
Melese, A., Bekele, G., Molla, E., Banga, D., Agena, A., Loha, A., Samuel, T., Borie, Y. A., Tadesse, B., & Yeheyis, T. Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23086 · Cited by 9
Diagnostic Test Accuracy Review of Cytology for Squamous Intraepithelial Lesion and Squamous Cell Carcinoma of Uterine Cervix
Pyo, J., Kang, G., Yoon, H. K., & Kim, H. J. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e16 · Cited by 9
Post-coital bleeding: What is the incidence of significant gynaecological pathology in women referred for colposcopy?
Godfrey, M. A. L., Nikolopoulos, M., Povolotskaya, N., Chenoy, R., & Wuntakal, R. (2019) · Sexual & Reproductive Healthcare · doi:10.1016/j.srhc.2019.100462 · Cited by 9
Shotgun Lipidomics for Differential Diagnosis of HPV-Associated Cervix Transformation
Starodubtseva, N. L., Chagovets, V., Nekrasova, M. E., Мирзоевна, Н. Н., Tokareva, A., Bourmenskaya, O., Attoeva, D. I., Kukaev, E., Trofimov, D. Y., Евгеньевич, Ф. В., et al. (2022) · Metabolites · doi:10.3390/metabo12060503 · Cited by 10
Evaluation of Urine and Vaginal Self-Sampling versus Clinician-Based Sampling for Cervical Cancer Screening: A Field Comparison of the Acceptability of Three Sampling Tests in a Rural Community of Cuenca, Ecuador
Vega, B., Neira, V. A., Ortíz, J., Maldonado-Rengel, R., López, D., Gómez, A., Vicuña, M. J., Chicaiza, J. V. M., Benoy, I. H., Parrón-Carreño, T., et al. (2022) · Healthcare · doi:10.3390/healthcare10091614 · Cited by 11
Meta-analysis of the correlation between vaginal microenvironment and HPV infection.
Fu, J., & Zhang, H. (2023) · PubMed Central · Cited by 9
Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology
Zhang, H., Varma, K. R., Han, M. C., Matsko, J., & Zhao, C. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22017 · Cited by 9
Impact of HPV molecular testing with partial genotyping as a feasibility study in cervical cancer community screening program in South India
Ramshankar, V., Ravindran, S., Arun, K., Albert, K., Sri, S. L., Ramasubramanian, L., & Satyaseelan, B. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28715 · Cited by 8
Cervical cancer screening in Brazilian Amazon Indigenous women: Towards the intensification of public policies for prevention
Novais, I. R., Coelho, C., Machado, H. D. C., Surita, F. G., Zeferino, L. C., & Vale, D. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294956 · Cited by 8
Cervical cancer screening program in Indonesia: is it time for HPV-DNA tests? Results of a qualitative study exploring the stakeholders’ perspectives
Ekawati, F. M., Listiani, P., Idaiani, S., Thobari, J. A., & Hafidz, F. (2024) · BMC Women s Health · doi:10.1186/s12905-024-02946-y · Cited by 8
Development, Validation, and Implementation of an Augmented Multiwell, Multitarget Quantitative PCR for the Analysis of Human Papillomavirus Genotyping through Software Automation, Data Science, and Artificial Intelligence
Pereira, A. R., Redzic, N., Vooren, S. V., Pelak, K., Broekmans, A. W., Desloovere, G., Broeck, D. V., Kehoe, K., Bogers, J., Coppens, A., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.05.012 · Cited by 8
A novel methylation-detection panel for HPV associated high-grade squamous intraepithelial lesion and cervical cancer screening
Cheng, X., Chai, R., Zhang, T., Chen, Y., Fan, F., Ye, Y., Jin, G., Li, T., Wang, H., Ding, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75047-3 · Cited by 8
Recomendaciones de prevención del cáncer. Actualización 2024
Bartolomé-Moreno, C., Melús-Palazón, E., Vallespín, C. V., Arana-Ballestar, S., Gallego, M., Navarro, J., & Bellas-Beceiro, B. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103128 · Cited by 8
Lineages and sublineages of high-risk human papillomavirus types associated with cervical cancer and precancer: a systematic review and meta-analysis
van den Borst, E., Bell, M., de Beeck, K. O., Camp, G. V., Keer, S. V., & Vorsters, A. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf118 · Cited by 10
Human Papillomavirus: An Old New History
West, N., Boz, V., Zanotta, N., Cason, C., Campisciano, G., Casuccio, A., Gianfrilli, D., Fasciana, T., Capra, G., Salfa, M. C., et al. (2025) · Pathogens · doi:10.3390/pathogens14101043 · Cited by 8
Qualitative Evidence Synthesis on Self-Collection for Human Papillomavirus–Based Cervical Screening: Protocol for Systematic Review
Camara, H., Zhang, Y., Lafferty, L., Vallely, A. J., Guy, R., & Kelly‐Hanku, A. (2020) · JMIR Research Protocols · doi:10.2196/21093 · Cited by 7
Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples
Leung, S. O. A., Feldman, S., Kalyanaraman, R., Shanmugam, V., Worley, M. J., Berkowitz, R. S., Horowitz, N. S., Feltmate, C. M., Muto, M. G., Lee, L. J., et al. (2021) · American Journal of Reproductive Immunology · doi:10.1111/aji.13394 · Cited by 8
A global perspective on cervical cancer screening: a literature review
Rauf, L., Eid, A., & Hamed, E. S. (2023) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20231044 · Cited by 8
A New Brazilian Device for Cervical Cancer Screening: Acceptability and Accuracy of Self-sampling
Lichtenfels, M., Lorenzi, N. P. C., Tacla, M., Yokochi, K., Frustockl, F. C., Silva, C. A., da Silva, A. L., Termini, L., & de Farias, C. B. (2023) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0043-1770134 · Cited by 10
Primary care experiences in the ‘Let’s test for HPV’ study: a qualitative analysis
Borchowsky, K., Rush, M., Mullally, T., McBain, L., Hudson, B., McMenamin, J., Smith, D., Sykes, P. H., & Garrett, S. M. (2023) · Journal of Primary Health Care · doi:10.1071/hc23038 · Cited by 8
Canadine inhibits epithelial mesenchymal transformation of HPV-negative cervical cancer
Ma, Y., Yang, Q., Gu, D., Yuan, X., Wang, Y., & Guo, L. (2023) · Tissue Barriers · doi:10.1080/21688370.2023.2256641 · Cited by 8
Evaluation of a novel vaginal cells self‐sampling device for human papillomavirus testing in cervical cancer screening: A clinical trial assessing reliability and acceptability
Yang, C., Chang, T., Chou, H., Chao, A., Hsu, S., Shih, Y., Huang, H., Lin, C.-T., Chen, M., Sun, L., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10653 · Cited by 8

Authors: Koliopoulos, G., Nyaga, V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R. A., Schünemann, H., Paraskevaidis, E., & Arbyn, M.
Affiliations: General-Maternity District Hospital Helena Venizelou (GR)
Institut Scientifique de Santé Publique (BE)
McMaster University (CA)
Newcastle University (GB)
Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust; Gynaecological Oncology Unit; Sharoe Green Lane Fullwood Preston Lancashire UK PR2 9HT
University Hospital of Ioannina (GR)
Sciensano (Belgium) (BE)
ORCID: Nyaga, Victoria N
Santesso, Nancy
Bryant, Andrew
Mustafa, Reem A
Schünemann, Holger
Paraskevaidis, Evangelos
Arbyn, Marc
Venue: Cochrane Database of Systematic Reviews
Publisher: Wiley
Published: 2017-08-10
Volume: 2018
Issue: 7
Pages: CD008587-CD008587
ISSN: 1361-6137 (ISSN-L)
1465-1858
DOI: 10.1002/14651858.cd008587.pub2
PMC: PMC6483676
OpenAlex: W2171104009
Cited by: 494
References: 145
Citations by year: 2026: 25 · 2025: 71 · 2024: 82 · 2023: 61 · 2022: 70 · 2021: 72 · 2020: 52 · 2019: 40 · 2018: 16
FWCI: 3.92
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
onlinelibrary.wiley.com/termsAndConditions (vor)
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: European Commission (603019)
Topics: Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords: cervical cancer screening, HPV testing, cervical cytology, cervical intraepithelial neoplasia, CIN 2, CIN3, adenocarcinoma in situ, Hybrid Capture 2, HPV genotyping, liquid-based cytology, diagnostic accuracy, sensitivity and specificity, primary screening, test comparison, screening thresholds, bias assessment, QUADAS
MeSH terms: Adult, Aged, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female, Humans, Middle Aged, Precancerous Conditions, Sensitivity and Specificity, Vaginal Smears, Polymerase Chain Reaction, Papillomavirus Infections, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cytology versus HPV testing for cervical cancer screening in the general population

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks